These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28824237)

  • 1. Validation of MASCC Score for Risk Stratification in Patients of Hematological Disorders with Febrile Neutropenia.
    Taj M; Nadeem M; Maqsood S; Shah T; Farzana T; Shamsi TS
    Indian J Hematol Blood Transfus; 2017 Sep; 33(3):355-360. PubMed ID: 28824237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
    Uys A; Rapoport BL; Anderson R
    Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?
    Paesmans M; Klastersky J; Maertens J; Georgala A; Muanza F; Aoun M; Ferrant A; Rapoport B; Rolston K; Ameye L
    Support Care Cancer; 2011 Jul; 19(7):1001-8. PubMed ID: 20596732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
    Ahn S; Rice TW; Yeung SJ; Cooksley T
    Support Care Cancer; 2018 May; 26(5):1465-1470. PubMed ID: 29168032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network.
    Hui EP; Leung LK; Poon TC; Mo F; Chan VT; Ma AT; Poon A; Hui EK; Mak SS; Lai M; Lei KI; Ma BB; Mok TS; Yeo W; Zee BC; Chan AT
    Support Care Cancer; 2011 Oct; 19(10):1625-35. PubMed ID: 20820815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms.
    Combariza JF; Lombana M; Pino LE; Arango M
    Support Care Cancer; 2015 Apr; 23(4):1009-13. PubMed ID: 25270848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of MASCC score in the inpatient management of febrile neutropenia: a single-center retrospective study.
    Bhardwaj PV; Emmich M; Knee A; Ali F; Walia R; Roychowdhury P; Clark J; Sridhar A; Lagu T; Loh KP
    Support Care Cancer; 2021 Oct; 29(10):5905-5914. PubMed ID: 33761002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of serum uric acid level and Multinational Association for Supportive Care in Cancer risk score on febrile neutropenia mortality.
    Sütcüoğlu O; Akdoğan O; İnci BK; Gürler F; Özdemir N; Yazıcı O
    Support Care Cancer; 2021 Feb; 29(2):1047-1053. PubMed ID: 32583058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
    Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
    Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department.
    Coyne CJ; Le V; Brennan JJ; Castillo EM; Shatsky RA; Ferran K; Brodine S; Vilke GM
    Ann Emerg Med; 2017 Jun; 69(6):755-764. PubMed ID: 28041827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients.
    de Souza Viana L; Serufo JC; da Costa Rocha MO; Costa RN; Duarte RC
    Support Care Cancer; 2008 Jul; 16(7):841-6. PubMed ID: 17960431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
    Baskaran ND; Gan GG; Adeeba K
    Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department.
    García de Guadiana-Romualdo L; Cerezuela-Fuentes P; Español-Morales I; Esteban-Torrella P; Jiménez-Santos E; Hernando-Holgado A; Albaladejo-Otón MD
    Biochem Med (Zagreb); 2019 Feb; 29(1):010702. PubMed ID: 30591812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis.
    Zheng B; Toarta C; Cheng W; Taljaard M; Reaume N; Perry JJ
    Crit Rev Oncol Hematol; 2020 May; 149():102922. PubMed ID: 32244162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
    Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
    Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CISNE versus MASCC: Identifying low risk febrile neutropenic patients.
    Mohindra R; Mathew R; Yadav S; Aggarwal P
    Am J Emerg Med; 2020 Nov; 38(11):2259-2263. PubMed ID: 31864874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the clinical Index of Stable febrile neutropenia risk stratification system for management of febrile neutropenia in gynecologic oncology patients.
    Monuszko KA; Albright B; Katherine Montes De Oca M; Thao Thi Nguyen N; Havrilesky LJ; Davidson BA
    Gynecol Oncol Rep; 2021 Aug; 37():100853. PubMed ID: 34504931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas.
    Wang XJ; Goh DYT; Dorajoo SR; Chan A
    Support Care Cancer; 2017 Sep; 25(9):2815-2822. PubMed ID: 28401314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Serum Procalcitonin Levels in Patients With Febrile Neutropenia Presenting to the Emergency Department.
    Yadav S; Mathew R; Sahu AK; Jamshed N; Mohindra R; Aggarwal P; Batra A; Halder D; Brunda RL
    J Emerg Med; 2021 May; 60(5):641-647. PubMed ID: 33518374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can MASCC and CISNE scores predict delays of lung cancer chemotherapy after febrile neutropenia?
    Ono Y; Hayama N; Hattori S; Ito Y; Oguma T; Sakamaki F; Asano K
    Thorac Cancer; 2022 Dec; 13(24):3504-3509. PubMed ID: 36330990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.